サイト内検索


登録済み会員ログイン




未登録の方はこちらから登録できます。
新規会員登録


ご利用案内

ご利用案内


連絡先

TEL.03-5812-5270
FAX.03-3831-0495
E-mail:info@spi-information.com


関連サイト・サービス

市場調査のご依頼、専門分野のイベント・フォーラムの開催などは シード・プランニングにて承っております。

シードプランニング

世界の医療・医薬品産業レポートのデータベースサービスは、sekairyo.comにてご利用いただけます。

sekairyo.com

医療従事者へのあらゆる形態の調査は、メドサークルにお任せ下さい。

メドサークル


セキュリティについて

当サイトのコンテンツ利用時に送信される機密情報は、Verisign認証の元暗号化されて送信されます。


Global Cancer Monoclonal Antibodies Market &Clinical Trial Insight 2024

世界の癌モノクローナル抗体市場&治験インサイト2024

レポート概要

本レポートは、以下について取り上げます。

  • 癌治療のためのモノクローナル抗体の意義
  • 世界の癌モノクローナル抗体の市場概要
  • フェーズ&適応症による世界の癌モノクローナル抗体パイプライン
  • 世界の癌モノクローナル抗体パイプライン:697 mAb
  • 既存の癌モノクローナル抗体:60製品
  • 世界の癌モノクローナル抗体市場機会:1400億ドル

近年、モノクローナル抗体の出現を目の当たりにしており、モノクローナル抗体は、毒性が低く、患者にとってより有効な治療選択肢を提供する可能性があります。過去数十年にわたり、研究者は人体の免疫系についての研究を増しており、この間にかなりの数の規制上の画期的出来事が行われてきました。癌を治療するためのmAbの使用は著しく増えています。これらの薬剤の市場性の高まりにより、製薬企業は、より効率的なmAbを開発するため、身体の免疫系にさらに大きな洞察をもたらす能力を有する新規の併用アプローチを開発することができました。

モノクローナル抗体は既に多くの癌治療の重要な部分ですが、癌治療の他の側面でのこれらの抗体の使用は未だ開発されていません。これに関して、現在のところ、癌細胞が正常細胞とは異なるプロセスおよび理由、ならびにこれらの差を利用するためのmAbの使用を深く理解する研究が行われています。これにより、より多くのより新しい形態のmAbが開発され、これが薬物または他の物質に結合され、より強力になります。

製薬企業は、これらの薬をより安全かつ効果的にする方法と手段を探しています。例として、mAbはタンパク質であるため、これらの抗体が身体の免疫系をそれらに対して反応させる可能性が高く、多くの副作用をもたらし、またmAbの破壊を招く可能性が高くなります。新しく開発された形態のmAbはこの問題に対する解決策であり、免疫反応を引き起こす可能性は低くなっています。

製薬企業はまた、即時型治療薬を開発するために抗体の特定の部分のみを使用するための選択肢に取り組んでいます。現在分析されている別のアプローチは、2つの抗体の部分を一緒に組み合わせることです(二重特異性抗体として知られています)。このプロセスでは、一方は癌細胞に付着し、他方は免疫細胞に付着して、最終的に両者を結びつける可能性があります。したがって今後は、より良い治療オプションを提供し、それにより患者の生活を改善するため、癌を治療する際に様々な形態のmAbの使用が増加する可能性が高くなっています。製薬企業は、この分野でのmAbの可能性を認識し、早期にこれらの抗体を開発することに重点を置いて、大きな市場シェアを獲得しています。

今後10年間で、新しい腫瘍特異的タンパク質の発見および導入により、より新しいmAb標的が、腫瘍細胞増殖の調節またはアポトーシスの誘導に関して首尾よく同定されると予想されます。さらに、mAbの変化は、より効率的な放射性核種または細胞傷害性mAb薬物標的化を可能にするか、またはより良好な治療抗体をもたらす傾向がある宿主エフェクター機構のより効率的な活性化をもたらすでしょう。

サンプルを見る

レポート詳細

目次

1. Introduction to Monoclonal Antibodies
1.1 History of Development
1.2 Working of Monoclonal Antibodies

2. Monoclonal Antibodies Classification
2.1 Naked Monoclonal Antibodies
2.2 Conjugated Monoclonal Antibodies
2.2.1 Radiolabeled Antibodies
2.2.2 Chemolabeled Antibodies
2.2.3 Immunotoxins

3. Monoclonal Antibodies Mechanisms
3.1 Tumor Antigens as Targets of Antibodies
3.2 Development of Antibodies for Clinical Purposes
3.3 Complement Dependent Cytotoxicity (CDC)
3.4 Signal Transduction Changes

4. Significance for Monoclonal Antibodies for Cancer Treatment

5. Global Cancer Monoclonal Antibodies Market Overview
5.1 Current Market Scenario
5.2 Clinical Pipeline Insight

6. Global Cancer Monoclonal Antibodies Market Future Outlook

7. Global - Bladder Cancer Monoclonal Antibodies Clinical Pipeline by Company &Phase
7.1 Phase-I/II
7.2 Phase-II
7.3 Phase-III

8. Marketed Bladder Cancer Monoclonal Antibodies Clinical Insight
8.1 Durvalumab (Imfinzi)

9. Global - Blood Cancer Monoclonal Antibodies Clinical Pipeline by Company & Pase
9.1 Unknown
9.2 Research
9.3 Preclinical
9.4 Clinical
9.5 Phase-I
9.6 Phase-I/II
9.7 Phase-II
9.8 Phase-III
9.9 Preregistration

10. Marketed Blood Cancer Monoclonal Antibodies Clinical Insight
10.1 Daratumumab (DARZALEX)
10.2 Ofatumumab (Arzerra)
10.3 Obinutuzumab (GAZYVA, Gazyva & Gazyvaro)
10.4 Blinatumomab (Blincyto)
10.5 Elotuzumab (Empliciti)
10.6 Mogamulizumab (Poteligeo)
10.7 Alemtuzumab (Campath, Lemtrada, MabCampath, MabKampat & Remniq)
10.8 Brentuximab Vedotin (Adcetris)
10.9 Inotuzumab Ozogamicin (BESPONSA & Besponsa)
10.10 Rituximab Biosimilar (AcellBia, Acellbia & USMAL)
10.11 Rituximab Biosimilar (Blitzima, Ritemvia, Truxima & Tuxella)
10.12 Rituximab Biosimilar (Rixathon & Riximyo)
10.13 Gemtuzumab Ozogamicin (Mylotarg)
10.14 Ibritumomab Tiuxetan (Zevalin & Zevamab)
10.15 Rituximab Biosimilar (REDDITUX, Reditux & Tidecron)
10.16 Rituximab Biosimilar (Novex)
10.17 Rituximab Biosimilar (CIMAbior & RituxCIM)
10.18 Rituximab/Hyaluronidase (MabThera SC, RITUXAN SC & Rituxan Hycela)
10.19 Rituximab Biosimilar (Zytux)
10.20 Rituximab Biosimilar (RituxiRel, Toritz & Toritz RA)
10.21 Rituximab Biosimilar (Maball)
10.22 Rituximab Biosimilar (Kikuzubam)
10.23 Rituximab Biosimilar (Mabtas)

11. Global - Breast Cancer Monoclonal Antibodies Clinical Pipeline by Company &Phase
11.1 Unknown
11.2 Research
11.3 Preclinical
11.4 Phase-I
11.5 Phase-II
11.6 Phase-III
11.7 Preregistration
11.8 Registered

12. Marketed Breast Cancer Monoclonal Antibodies Clinical Insight
12.1 Trastuzumab Subcutaneous (Herceptin SC)
12.2 Pertuzumab (Omnitarg & Perjeta)
12.3 Trastuzumab Biosimilar (CANMAb, Hertraz, Ogivri & Zedora)
12.4 Trastuzumab Emtansine (Kadcyla)
12.5 Trastuzumab Biosimilar (Vivitra)

13. Global Bone Cancer Monoclonal Antibodies Clinical Pipeline by Company & Phae
13.1 Phase-III

14. Marketed Bone Cancer Monoclonal Antibodies Clinical Insight
14.1 Denosumab (PRALIA, Prolia, Ranmark & Xgeva)

15. Global - Brain Cancer Monoclonal Antibodies Clinical Pipeline by Company & hase
15.1 Preclinical
15.2 Phase-I/II
15.3 Phase-III
15.4 Registered

16. Marketed Brain Cancer Monoclonal Antibodies Clinical Insight
16.1 Dinutuximab (Unituxin)

17. Global - Cervical Cancer Monoclonal Antibodies Clinical Pipeline by Company &am; Phase
17.1 Phase-I/II

18. Global - Colorectal Cancer Monoclonal Antibodies Clinical pipeline by Company & Phase
18.1 Unknown
18.2 Preclinical
18.3 Phase-I

19. Global - Head and Neck Cancer Monoclonal Antibodies Clinical Pipeline by Company & Phase
19.1 Preclinical
19.2 Phase-I/II
19.3 Phase-III

20. Global - Liver Cancer Monoclonal Antibodies Clinical Pipeline by Company & hase
20.1 Phase-II

21. Global - Kidney Cancer Monoclonal Antibodies Clinical Pipeline by Company &Phase
21.1 Preclinical
21.2 Phase-II
21.3 Phase-III

22. Global - Skin Cancer Monoclonal Antibodies Clinical Pipeline by Company & Pase
22.1 Research
22.2 Preclinical
22.3 Phase-I
22.4 Phase-I/II
22.5 Phase-II/III
22.6 Phase-III
22.7 Preregistration

23. Marketed Skin Cancer Monoclonal Antibodies Clinical Insight
23.1 Avelumab (BAVENCIO)
23.2 Olaratumab (Lartruvo)

24. Global - Stomach Cancer Monoclonal Antibodies Clinical Pipeline by Company & Phase
24.1 Preclinical
24.2 Phase-I/II
24.3 Phase-II
24.4 Phase-III
24.5 Preregistration

25. Marketed Stomach Cancer Monoclonal Antibodies Clinical
25.1 Bevacizumab Biosimilar (Bevax)
25.2 Cetuximab Biosimilar - CinnaGen
25.3 Bevacizumab Biosimilar (Cizumab)

26. Global - Lung Cancer Monoclonal Antibodies Clinical Pipeline by Company & Pase
26.1 Research
26.2 Clinical
26.3 Phase-I
26.4 Phase-I/II
26.5 Phase-II
26.6 Phase-II/III
26.7 Phase-III
26.8 Preregistration
26.9 Registered

27. Marketed Lung Cancer Monoclonal Antibodies Clinical Insight
27.1 Necitumumab (Portrazza)
27.2 Iodine I 131 Derlotuximab Biotin (Cotara)
27.3 Bevacizumab Biosimilar (Bryxta)
27.4 Racotumomab (Vaxira)
27.5 Racotumomab (Vaxira)
27.6 Tc 99m Nofetumomab Merpentan (VerLuma)

28. Global - Ovarian Cancer Monoclonal Antibodies Clinical Pipeline by Company & Phase
28.1 Research
28.2 Preclinical
28.3 Phase-I
28.4 Phase-I/II
28.5 Phase-II

29. Global - Pancreatic Cancer Monoclonal Antibodies Clinical Pipeline by Company & Phase
29.1 Preclinical
29.2 Phase-I
29.3 Phase-I/II
29.4 Phase-II

30. Marketed Pancreatic Cancer Monoclonal Antibodies Clinical Insight
30.1 Gemcitabine elaidate companion diagnostic - Ventana Medical Systems/Clovis Oncology

31. Global - Prostate Cancer Monoclonal Antibodies Clinical Pipeline by Company &am; Phase
31.1 Preclinical
31.2 Phase-II

32. Global - Multiple Cancer Monoclonal Antibodies Clinical Pipeline by Company &am; Phase
32.1 Unknown
32.2 Research
32.3 Preclinical
32.4 Clinical
32.5 Phase-I
32.6 Phase-I/II
32.7 Phase-II
32.8 Phase-II/III
32.9 Phase-III
32.10 Registered

33. Marketed Multiple Cancer Monoclonal Antibodies Clinical Insight
33.1 Cetuximab (Erbitux)
33.2 Nivolumab (Opdivo)
33.3 Bevacizumab (Avastin)
33.4 Trastuzumab (Herceptin)
33.5 Atezolizumab (TECENTRIQ)
33.6 Rituximab (MabThera & Rituxan)
33.7 Ramucirumab (Cyramza, Sairamza & Silamza)
33.8 Trastuzumab Biosimilar (Herzuma)
33.9 Pembrolizumab (Keytruda)
33.10 Pembrolizumab Companion Diagnostic (PD-L1 IHC 22C3 pharmDx)
33.11 Ipilimumab (Yervoy)
33.12 Trastuzumab Biosimilar (BIOMAb EGFR, CIMAher, Cimaher, Taixinsheng, TheraCIM, Theraloc & VECTHIX)
33.13 Nimotuzumab (BIOMAb EGFR, CIMAher, Cimaher, Taixinsheng, TheraCIM, Theraloc & VECTHIX)
33.14 Bevacizumab Biosimilar (KRABEVA)
33.15 Bevacizumab Biosimilar (Mvasi)
33.16 Trastuzumab Biosimilar (AryoTrust)
33.17 Satumomab (OncoScint CR/OV)

34. Competitive Landscape
34.1 Abbvie
34.2 Amgen
34.3 Bayer HealthCare
34.4 Biogen Idec
34.5 Eli Lilly
34.6 Genmab
34.7 Gilead Sciences
34.8 GlaxoSmithKline
34.9 Novartis
34.10 Pfizer
34.11 Roche
34.12 Seattle Genetics

Figure 1-1: History of Development of Monoclonal Antibodies
Figure 1-2: Working of Monoclonal Antibodies
Figure 2-1: Types of Monoclonal Antibodies
Figure 5-1: Global Biologics Market Classification
Figure 5-2: Global Market for Monoclonal Antibodies (US$ Billion), 2018-2024
Figure 5-3: Global - Bladder Cancer Monoclonal Antibodies Clinical Pipeline by Phase (%), 2018 till 2024
Figure 5-4: Global - Bladder Cancer Monoclonal Antibodies Clinical Pipeline by Phase (Number), 2018 till 2024
Figure 5-5: Global - Blood Cancer Monoclonal Antibodies Clinical Pipeline by Phase (%), 2018 till 2024
Figure 5-6: Global - Blood Cancer Monoclonal Antibodies Clinical Pipeline by Phase (Number), 2018 till 2024
Figure 5-7: Global - Breast Cancer Monoclonal Antibodies Clinical Pipeline by Phase (%), 2018 till 2024
Figure 5-8: Global - Breast Cancer Monoclonal Antibodies Clinical Pipeline by Phase (Number), 2018 till 2024
Figure 5-9: Global - Bone Cancer Monoclonal Antibodies Clinical Pipeline by Phase (%), 2018 till 2024
Figure 5-10: Global - Bone Cancer Monoclonal Antibodies Clinical Pipeline by Phase (Number), 2018 till 2024
Figure 5-11: Global - Brain Cancer Monoclonal Antibodies Clinical Pipeline by Phase (%), 2018 till 2024
Figure 5-12: Global - Brain Cancer Monoclonal Antibodies Clinical Pipeline by Phase (Number), 2018 till 2024
Figure 5-13: Global - Colorectal Cancer Monoclonal Antibodies Clinical Pipeline by Phase (%), 2018 till 2024
Figure 5-14: Global - Colorectal Cancer Monoclonal Antibodies Clinical Pipeline by Phase (Number), 2018 till 2024
Figure 5-15: Global - Head and Neck Cancer Monoclonal Antibodies Clinical Pipeline by Phase (%), 2018 till 2024
Figure 5-16: Global - Head and Neck Cancer Monoclonal Antibodies Clinical Pipeline by Phase (Number), 2018 till 2024
Figure 5-17: Global - Kidney Cancer Monoclonal Antibodies Clinical Pipeline by Phase (%), 2018 till 2024
Figure 5-18: Global - Kidney Cancer Monoclonal Antibodies Clinical Pipeline by Phase (Number), 2018 till 2024
Figure 5-19: Global - Skin Cancer Monoclonal Antibodies Clinical Pipeline by Phase (%), 2018 till 2024
Figure 5-20: Global - Skin Cancer Monoclonal Antibodies Clinical Pipeline by Phase (Number), 2018 till 2024
Figure 5-21: Global - Stomach Cancer Monoclonal Antibodies Clinical Pipeline by Phase (%), 2018 till 2024
Figure 5-22: Global - Stomach Cancer Monoclonal Antibodies Clinical Pipeline by Phase (Number), 2018 till 2024
Figure 5-23: Global - Lung Cancer Monoclonal Antibodies Clinical Pipeline by Phase (%), 2018 till 2024
Figure 5-24: Global - Lung Cancer Monoclonal Antibodies Clinical Pipeline by Phase (Number), 2018 till 2024
Figure 5-25: Global - Ovarian Cancer Monoclonal Antibodies Clinical Pipeline by Phase (%), 2018 till 2024
Figure 5-26: Global - Ovarian Cancer Monoclonal Antibodies Clinical Pipeline by Phase (Number), 2018 till 2024
Figure 5-27: Global - Pancreatic Cancer Monoclonal Antibodies Clinical Pipeline by Phase (%), 2018 till 2024
Figure 5-28: Global - Pancreatic Cancer Monoclonal Antibodies Clinical Pipeline by Phase (Number), 2018 till 2024
Figure 5-29: Global - Prostate Cancer Monoclonal Antibodies Clinical Pipeline by Phase (%), 2018 till 2024
Figure 5-30: Global - Prostate Cancer Monoclonal Antibodies Clinical Pipeline by Phase (Number), 2018 till 2024
Figure 5-31: Global - Multiple Cancer Monoclonal Antibodies Clinical Pipeline by Phase (Number), 2018 till 2024
Figure 5-32: Global - Multiple Cancer Monoclonal Antibodies Clinical Pipeline by Phase (%), 2018 till 2024
Figure 5-33: Global - Cancer Monoclonal Antibodies Clinical Pipeline by Phase (%), 2018 till 2024
Figure 5-34: Global - Cancer Monoclonal Antibodies Clinical Pipeline by Phase (Number), 2018 till 2024

1. Introduction to Monoclonal Antibodies
1.1 History of Development
1.2 Working of Monoclonal Antibodies

2. Monoclonal Antibodies Classification
2.1 Naked Monoclonal Antibodies
2.2 Conjugated Monoclonal Antibodies
2.2.1 Radiolabeled Antibodies
2.2.2 Chemolabeled Antibodies
2.2.3 Immunotoxins

3. Monoclonal Antibodies Mechanisms
3.1 Tumor Antigens as Targets of Antibodies
3.2 Development of Antibodies for Clinical Purposes
3.3 Complement Dependent Cytotoxicity (CDC)
3.4 Signal Transduction Changes

4. Significance for Monoclonal Antibodies for Cancer Treatment

5. Global Cancer Monoclonal Antibodies Market Overview
5.1 Current Market Scenario
5.2 Clinical Pipeline Insight

6. Global Cancer Monoclonal Antibodies Market Future Outlook

7. Global - Bladder Cancer Monoclonal Antibodies Clinical Pipeline by Company &Phase
7.1 Phase-I/II
7.2 Phase-II
7.3 Phase-III

8. Marketed Bladder Cancer Monoclonal Antibodies Clinical Insight
8.1 Durvalumab (Imfinzi)

9. Global - Blood Cancer Monoclonal Antibodies Clinical Pipeline by Company & Pase
9.1 Unknown
9.2 Research
9.3 Preclinical
9.4 Clinical
9.5 Phase-I
9.6 Phase-I/II
9.7 Phase-II
9.8 Phase-III
9.9 Preregistration

10. Marketed Blood Cancer Monoclonal Antibodies Clinical Insight
10.1 Daratumumab (DARZALEX)
10.2 Ofatumumab (Arzerra)
10.3 Obinutuzumab (GAZYVA, Gazyva & Gazyvaro)
10.4 Blinatumomab (Blincyto)
10.5 Elotuzumab (Empliciti)
10.6 Mogamulizumab (Poteligeo)
10.7 Alemtuzumab (Campath, Lemtrada, MabCampath, MabKampat & Remniq)
10.8 Brentuximab Vedotin (Adcetris)
10.9 Inotuzumab Ozogamicin (BESPONSA & Besponsa)
10.10 Rituximab Biosimilar (AcellBia, Acellbia & USMAL)
10.11 Rituximab Biosimilar (Blitzima, Ritemvia, Truxima & Tuxella)
10.12 Rituximab Biosimilar (Rixathon & Riximyo)
10.13 Gemtuzumab Ozogamicin (Mylotarg)
10.14 Ibritumomab Tiuxetan (Zevalin & Zevamab)
10.15 Rituximab Biosimilar (REDDITUX, Reditux & Tidecron)
10.16 Rituximab Biosimilar (Novex)
10.17 Rituximab Biosimilar (CIMAbior & RituxCIM)
10.18 Rituximab/Hyaluronidase (MabThera SC, RITUXAN SC & Rituxan Hycela)
10.19 Rituximab Biosimilar (Zytux)
10.20 Rituximab Biosimilar (RituxiRel, Toritz & Toritz RA)
10.21 Rituximab Biosimilar (Maball)
10.22 Rituximab Biosimilar (Kikuzubam)
10.23 Rituximab Biosimilar (Mabtas)

11. Global - Breast Cancer Monoclonal Antibodies Clinical Pipeline by Company &Phase
11.1 Unknown
11.2 Research
11.3 Preclinical
11.4 Phase-I
11.5 Phase-II
11.6 Phase-III
11.7 Preregistration
11.8 Registered

12. Marketed Breast Cancer Monoclonal Antibodies Clinical Insight
12.1 Trastuzumab Subcutaneous (Herceptin SC)
12.2 Pertuzumab (Omnitarg & Perjeta)
12.3 Trastuzumab Biosimilar (CANMAb, Hertraz, Ogivri & Zedora)
12.4 Trastuzumab Emtansine (Kadcyla)
12.5 Trastuzumab Biosimilar (Vivitra)

13. Global Bone Cancer Monoclonal Antibodies Clinical Pipeline by Company & Phae
13.1 Phase-III

14. Marketed Bone Cancer Monoclonal Antibodies Clinical Insight
14.1 Denosumab (PRALIA, Prolia, Ranmark & Xgeva)

15. Global - Brain Cancer Monoclonal Antibodies Clinical Pipeline by Company & hase
15.1 Preclinical
15.2 Phase-I/II
15.3 Phase-III
15.4 Registered

16. Marketed Brain Cancer Monoclonal Antibodies Clinical Insight
16.1 Dinutuximab (Unituxin)

17. Global - Cervical Cancer Monoclonal Antibodies Clinical Pipeline by Company &am; Phase
17.1 Phase-I/II

18. Global - Colorectal Cancer Monoclonal Antibodies Clinical pipeline by Company & Phase
18.1 Unknown
18.2 Preclinical
18.3 Phase-I

19. Global - Head and Neck Cancer Monoclonal Antibodies Clinical Pipeline by Company & Phase
19.1 Preclinical
19.2 Phase-I/II
19.3 Phase-III

20. Global - Liver Cancer Monoclonal Antibodies Clinical Pipeline by Company & hase
20.1 Phase-II

21. Global - Kidney Cancer Monoclonal Antibodies Clinical Pipeline by Company &Phase
21.1 Preclinical
21.2 Phase-II
21.3 Phase-III

22. Global - Skin Cancer Monoclonal Antibodies Clinical Pipeline by Company & Pase
22.1 Research
22.2 Preclinical
22.3 Phase-I
22.4 Phase-I/II
22.5 Phase-II/III
22.6 Phase-III
22.7 Preregistration

23. Marketed Skin Cancer Monoclonal Antibodies Clinical Insight
23.1 Avelumab (BAVENCIO)
23.2 Olaratumab (Lartruvo)

24. Global - Stomach Cancer Monoclonal Antibodies Clinical Pipeline by Company & Phase
24.1 Preclinical
24.2 Phase-I/II
24.3 Phase-II
24.4 Phase-III
24.5 Preregistration

25. Marketed Stomach Cancer Monoclonal Antibodies Clinical
25.1 Bevacizumab Biosimilar (Bevax)
25.2 Cetuximab Biosimilar - CinnaGen
25.3 Bevacizumab Biosimilar (Cizumab)

26. Global - Lung Cancer Monoclonal Antibodies Clinical Pipeline by Company & Pase
26.1 Research
26.2 Clinical
26.3 Phase-I
26.4 Phase-I/II
26.5 Phase-II
26.6 Phase-II/III
26.7 Phase-III
26.8 Preregistration
26.9 Registered

27. Marketed Lung Cancer Monoclonal Antibodies Clinical Insight
27.1 Necitumumab (Portrazza)
27.2 Iodine I 131 Derlotuximab Biotin (Cotara)
27.3 Bevacizumab Biosimilar (Bryxta)
27.4 Racotumomab (Vaxira)
27.5 Racotumomab (Vaxira)
27.6 Tc 99m Nofetumomab Merpentan (VerLuma)

28. Global - Ovarian Cancer Monoclonal Antibodies Clinical Pipeline by Company & Phase
28.1 Research
28.2 Preclinical
28.3 Phase-I
28.4 Phase-I/II
28.5 Phase-II

29. Global - Pancreatic Cancer Monoclonal Antibodies Clinical Pipeline by Company & Phase
29.1 Preclinical
29.2 Phase-I
29.3 Phase-I/II
29.4 Phase-II

30. Marketed Pancreatic Cancer Monoclonal Antibodies Clinical Insight
30.1 Gemcitabine elaidate companion diagnostic - Ventana Medical Systems/Clovis Oncology

31. Global - Prostate Cancer Monoclonal Antibodies Clinical Pipeline by Company &am; Phase
31.1 Preclinical
31.2 Phase-II

32. Global - Multiple Cancer Monoclonal Antibodies Clinical Pipeline by Company &am; Phase
32.1 Unknown
32.2 Research
32.3 Preclinical
32.4 Clinical
32.5 Phase-I
32.6 Phase-I/II
32.7 Phase-II
32.8 Phase-II/III
32.9 Phase-III
32.10 Registered

33. Marketed Multiple Cancer Monoclonal Antibodies Clinical Insight
33.1 Cetuximab (Erbitux)
33.2 Nivolumab (Opdivo)
33.3 Bevacizumab (Avastin)
33.4 Trastuzumab (Herceptin)
33.5 Atezolizumab (TECENTRIQ)
33.6 Rituximab (MabThera & Rituxan)
33.7 Ramucirumab (Cyramza, Sairamza & Silamza)
33.8 Trastuzumab Biosimilar (Herzuma)
33.9 Pembrolizumab (Keytruda)
33.10 Pembrolizumab Companion Diagnostic (PD-L1 IHC 22C3 pharmDx)
33.11 Ipilimumab (Yervoy)
33.12 Trastuzumab Biosimilar (BIOMAb EGFR, CIMAher, Cimaher, Taixinsheng, TheraCIM, Theraloc & VECTHIX)
33.13 Nimotuzumab (BIOMAb EGFR, CIMAher, Cimaher, Taixinsheng, TheraCIM, Theraloc & VECTHIX)
33.14 Bevacizumab Biosimilar (KRABEVA)
33.15 Bevacizumab Biosimilar (Mvasi)
33.16 Trastuzumab Biosimilar (AryoTrust)
33.17 Satumomab (OncoScint CR/OV)

34. Competitive Landscape
34.1 Abbvie
34.2 Amgen
34.3 Bayer HealthCare
34.4 Biogen Idec
34.5 Eli Lilly
34.6 Genmab
34.7 Gilead Sciences
34.8 GlaxoSmithKline
34.9 Novartis
34.10 Pfizer
34.11 Roche
34.12 Seattle Genetics

Figure 1-1: History of Development of Monoclonal Antibodies
Figure 1-2: Working of Monoclonal Antibodies
Figure 2-1: Types of Monoclonal Antibodies
Figure 5-1: Global Biologics Market Classification
Figure 5-2: Global Market for Monoclonal Antibodies (US$ Billion), 2018-2024
Figure 5-3: Global - Bladder Cancer Monoclonal Antibodies Clinical Pipeline by Phase (%), 2018 till 2024
Figure 5-4: Global - Bladder Cancer Monoclonal Antibodies Clinical Pipeline by Phase (Number), 2018 till 2024
Figure 5-5: Global - Blood Cancer Monoclonal Antibodies Clinical Pipeline by Phase (%), 2018 till 2024
Figure 5-6: Global - Blood Cancer Monoclonal Antibodies Clinical Pipeline by Phase (Number), 2018 till 2024
Figure 5-7: Global - Breast Cancer Monoclonal Antibodies Clinical Pipeline by Phase (%), 2018 till 2024
Figure 5-8: Global - Breast Cancer Monoclonal Antibodies Clinical Pipeline by Phase (Number), 2018 till 2024
Figure 5-9: Global - Bone Cancer Monoclonal Antibodies Clinical Pipeline by Phase (%), 2018 till 2024
Figure 5-10: Global - Bone Cancer Monoclonal Antibodies Clinical Pipeline by Phase (Number), 2018 till 2024
Figure 5-11: Global - Brain Cancer Monoclonal Antibodies Clinical Pipeline by Phase (%), 2018 till 2024
Figure 5-12: Global - Brain Cancer Monoclonal Antibodies Clinical Pipeline by Phase (Number), 2018 till 2024
Figure 5-13: Global - Colorectal Cancer Monoclonal Antibodies Clinical Pipeline by Phase (%), 2018 till 2024
Figure 5-14: Global - Colorectal Cancer Monoclonal Antibodies Clinical Pipeline by Phase (Number), 2018 till 2024
Figure 5-15: Global - Head and Neck Cancer Monoclonal Antibodies Clinical Pipeline by Phase (%), 2018 till 2024
Figure 5-16: Global - Head and Neck Cancer Monoclonal Antibodies Clinical Pipeline by Phase (Number), 2018 till 2024
Figure 5-17: Global - Kidney Cancer Monoclonal Antibodies Clinical Pipeline by Phase (%), 2018 till 2024
Figure 5-18: Global - Kidney Cancer Monoclonal Antibodies Clinical Pipeline by Phase (Number), 2018 till 2024
Figure 5-19: Global - Skin Cancer Monoclonal Antibodies Clinical Pipeline by Phase (%), 2018 till 2024
Figure 5-20: Global - Skin Cancer Monoclonal Antibodies Clinical Pipeline by Phase (Number), 2018 till 2024
Figure 5-21: Global - Stomach Cancer Monoclonal Antibodies Clinical Pipeline by Phase (%), 2018 till 2024
Figure 5-22: Global - Stomach Cancer Monoclonal Antibodies Clinical Pipeline by Phase (Number), 2018 till 2024
Figure 5-23: Global - Lung Cancer Monoclonal Antibodies Clinical Pipeline by Phase (%), 2018 till 2024
Figure 5-24: Global - Lung Cancer Monoclonal Antibodies Clinical Pipeline by Phase (Number), 2018 till 2024
Figure 5-25: Global - Ovarian Cancer Monoclonal Antibodies Clinical Pipeline by Phase (%), 2018 till 2024
Figure 5-26: Global - Ovarian Cancer Monoclonal Antibodies Clinical Pipeline by Phase (Number), 2018 till 2024
Figure 5-27: Global - Pancreatic Cancer Monoclonal Antibodies Clinical Pipeline by Phase (%), 2018 till 2024
Figure 5-28: Global - Pancreatic Cancer Monoclonal Antibodies Clinical Pipeline by Phase (Number), 2018 till 2024
Figure 5-29: Global - Prostate Cancer Monoclonal Antibodies Clinical Pipeline by Phase (%), 2018 till 2024
Figure 5-30: Global - Prostate Cancer Monoclonal Antibodies Clinical Pipeline by Phase (Number), 2018 till 2024
Figure 5-31: Global - Multiple Cancer Monoclonal Antibodies Clinical Pipeline by Phase (Number), 2018 till 2024
Figure 5-32: Global - Multiple Cancer Monoclonal Antibodies Clinical Pipeline by Phase (%), 2018 till 2024
Figure 5-33: Global - Cancer Monoclonal Antibodies Clinical Pipeline by Phase (%), 2018 till 2024
Figure 5-34: Global - Cancer Monoclonal Antibodies Clinical Pipeline by Phase (Number), 2018 till 2024

発刊日

2018/11/01

体裁

PDF / 1100ページ

販売価格

3,000USD

発行

PNS Pharma

備考

※ご請求は、お申込日のTTSレートで円換算し、消費税を加えた金額になります。
※販売価格はシングルユーザーライセンスのものとなります。他のライセンス形態・価格に関しましてはご相談下さい。
※本レポートは、英文です。PDF(電子媒体)での納品となります。
※本レポートは取り寄せとなりますので、申し込みからお届けまで、多少時間が掛かる場合がございます。

関連カテゴリ

疾病別治療・領域別治療

購入・お問い合わせ

このレポートを購入

詳細を問い合わせる


PAGE